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most of the agents monitored, quinolone-resistant E. coli
was over 70% and 56.0% of the germ was extended spectrum
b-lactamase (ESBL) positive, especially, the resistant rate of
E. coli against the third and fourth generation cephalosporin
(including ceftazidime) was higher than 60%. 24.8%-
41.7% of glucose non-fermented bacteria were resistant
to meropenem, and the resistant rate of Acinetobacter
baumannii overtook that of P. aeruginosa.
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CS6.2 Re-emergence of Chikungunya virus
Y. Poovorawan*. Center of Excellence in Clinical
Virology, Department of Pediatrics, Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand
Background: Chikungunya, a vector-borne disease, has
recently re-emerged. Not only has Chikungunya caused
major public health problems in several regions of the
world but its outbreaks have also had a signiﬁcant impact on
the global economy. Chikungunya is caused by Chikungunya
virus (CHIKV) which is transmitted by Aedes mosquitoes as
its major vectors. Clinical manifestations of Chikungunya
include high grade fever, severe arthralgia, myalgia and
maculopapular rash.
Aims: This study has reviewed re-emergence of Chikungunya
virus especially in Asia and Africa.
Methods: Available information on Chikungunya virus
infection was selected from our research in Thailand and
the literature.
Results and Conclusions: CHIKV was ﬁrst isolated in
Tanzania in 1952. Since then, numerous outbreaks have
been reported in the tropical countries of Asia and Africa.
Phylogenetic analysis based on E1 gene sequences has
identiﬁed three genotypes of CHIKV, East Central and
Southeast African (ECSA), West African and Asian genotypes.
CHIKV has been circulating in several countries in Asia and
was initially isolated in Thailand in 1958. From 1990 to
2005, the frequency of Chikungunya outbreaks in Asia has
declined. In 2005, reemergence of Chikungunya caused by
the ECSA strain was conﬁrmed on Reunion Island and CHIKV
has rapidly spread to India in 2007. Several genome analyses
have shown that mutation of CHIKV at position A226V of
the E1gene increases transmissibility of CHIKV by Aedes
albopictus mosquitoes. Thailand has experienced several
outbreaks of Chikungunya since September 2008. Studies
have shown that Chikungunya was introduced to the south
of Thailand from India via Sri Lanka and Indonesia and was
caused by the ECSA strain harboring the A226V mutation of
the E1 gene identical to the strains isolated from Reunion
Island. The outbreaks were mostly conﬁned to the south of
the country where Para rubber plantations are abundant and
Aedes albopictus mosquitoes are endemic. The outbreaks
reached a peak in 2009 and have gradually decreased
since 2010. These Chikungunya outbreaks have had a major
impact on public health and Thailand’s economy.
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New treatments are urgently needed to combat the growing
number of dengue fever cases in more than 100 countries
around the world where the virus is endemic. The infected
cases exhibit a broad spectrum of clinical symptoms, ranging
from being fully asymptomatic to causing life-threatening
conditions like dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS). There are no effective antivirals or
safe vaccines available to protect against the four closely
related but antigenically distinct dengue viruses.
Several compounds or antibodies that target viral entry
or viral replication have been reported, however their
progression to the clinic has been somewhat challenging
because there are no animal models that suitably mimic the
spectrum of human disease. A viremia model in AG129 mice
has been shown to be useful for testing compounds and
biologics. Additionally, Antibody Dependent Enhancement
(ADE) infection by DENV in AG129 mice, where passive
immunity using low concentration of anti-DENV antibody,
exacerbated dengue disease severity with small intestinal
hemorrhage and decreased survival time post-infection have
been established. These advances, together with efforts to
introduce “repurposed” drugs such as chloroquine to treat
dengue can accelerate antiviral therapies for dengue fever.
The current status of dengue antiviral development will be
reviewed and some recent data with “repurposed” drugs
will be presented.
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resistance: when two worlds collide
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The ongoing saga over the name of the NDM-1 gene obscures,
sometimes deliberately so, the over aching problems of
holistically negating the continued spread of antibiotic
resistance. Genetic ﬂuidity and plasticity aside, man’s
paradoxical behaviour both nationally and internationally
has spawned and aided and abetted “superbugs” that is
likely to herald the end of conventional treatment of
infectious diseases and plunge future generations into the
uncertainty of clinical outcomes more akin to the 19th
century. Patently, we are lacking global responsibility and
the means to deal with countries which continuously ignore
guidelines from the WHO and others.
This brief synopsis will not only outline the epidemiology of
NDM-1 and its genetics but also key risk factors in its spread
both throughout Southern Asia and globally.
